Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A3 | Q01959 | 11/20 | 0.60 |
| ▸ | SLC6A4 | P31645 | 7/20 | 0.60 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Brasofensine SCHEMBL1649206 | 1.00 | SLC6A3 (0.60) | SLC6A3SLC6A4SLC6A2 | |
| Brasofensine SCHEMBL20390946 | 1.00 | SLC6A3 (0.60) | SLC6A3SLC6A4SLC6A2 | |
| Brasofensine SCHEMBL14762214 | 1.00 | SLC6A3 (0.60) | SLC6A3SLC6A4SLC6A2 | |
| Brasofensine SCHEMBL20390950 | 1.00 | SLC6A3 (0.60) | SLC6A3SLC6A4SLC6A2 | |
| Brasofensine SCHEMBL5031138 | 0.94 | SLC6A3 (0.58) | SLC6A3SLC6A4SLC6A2 | |
| Brasofensine SCHEMBL29426326 | 0.92 | SLC6A3 (0.58) | SLC6A3SLC6A4SLC6A2 | |
| SCHEMBL3671497 | 0.89 | SLC6A3 (0.59) | SLC6A3SLC6A4SLC6A2 | |
| Hydrochloric Acid SCHEMBL7362088 | 0.88 | SLC6A3 (0.58) | SLC6A3SLC6A4SLC6A2 | |
| SCHEMBL7460089 | 0.86 | SLC6A3 (0.59) | SLC6A3SLC6A4SLC6A2 | |
| SCHEMBL7455410 | 0.86 | SLC6A3 (0.59) | SLC6A3SLC6A4SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1113 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025111482-A1 | COMPLEXING AGENT SALT FORMULATIONS OF PHARMACEUTICAL COMPOUNDS AT LOW STOICHIOMETRIC RATIOS | BEXSON BIOMEDICAL, INC. (US) | 2025-05-30 | — | — | WO | claimed |
| US-20250032503-A1 | USE OF APREPITANT FOR TREATING ALZHEIMER'S DISEASE | HOTH THERAPEUTICS, INC. | 2025-01-30 | — | — | US | claimed |
| EP-4360628-A2 | COMPOSITIONS AND METHODS FOR INCREASING THE METABOLIC LIFETIME OF DEXTROMETHORPHAN AND RELATED PHARMACODYNAMIC EFFECTS | Antecip Bioventures II LLC (US) | 2024-05-01 | — | — | EP | claimed |
| EP-4297868-A1 | USE OF APREPITANT FOR TREATING ALZHEIMER'S DISEASE | Hoth Therapeutics, Inc. (US) | 2024-01-03 | — | — | EP | claimed |
| US-20230285387-A1 | COMBINATION OF MORPHINAN COMPOUNDS AND ANTIDEPRESSANT FOR THE TREATMENT OF PSEUDOBULBAR AFFECT, NEUROLOGICAL DISEASES, INTRACTABLE AND CHRONIC PAIN AND BRAIN INJURY | CONCERT PHARMACEUTICALS, INC. | 2023-09-14 | — | — | US | claimed |
| EP-4106872-A1 | COMPOSITIONS AND METHODS FOR ASSESSING THE EFFICACY OF INHIBITORS OF NEUROTRANSMITTER TRANSPORTERS | Denovo Biopharma LLC (US) | 2022-12-28 | — | — | EP | claimed |
| US-11478467-B2 | Targeted drug rescue with novel compositions, combinations, and methods thereof | Exciva GmbH (DE) | 2022-10-25 | — | — | US | claimed |
| US-20220296586-A1 | NOVEL COMPOSITIONS, COMBINATIONS, AND METHODS THEREOF | Vepachedu, Sreenivasarao (US) | 2022-09-22 | — | — | US | claimed |
| WO-2022182658-A1 | USE OF APREPITANT FOR TREATING ALZHEIMER'S DISEASE | HOTH THERAPEUTICS, INC. (US) | 2022-09-01 | — | — | WO | claimed |
| EP-1931320-B1 | MICROPARTICLES WITH MODIFIED RELEASE OF AT LEAST ONE ACTIVE PRINCIPLE AND ORAL DOSAGE FORM COMPRISING THE SAME | FLAMEL IRELAND LTD (IE) | 2022-06-15 | — | — | EP | claimed |
| CN-101277684-A | Microparticles for the modified release of at least one active principle and oral pharmaceutical forms containing them | FLAMEL TECH SA (FR) | 2008-10-01 | — | — | CN | claimed |
| EP-1954244-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | Scidose, Llc (US) | 2008-08-13 | — | — | EP | claimed |
| EP-1931320-A2 | MICROPARTICLES WITH MODIFIED RELEASE OF AT LEAST ONE ACTIVE PRINCIPLE AND ORAL GALENIC FORM COMPRISING SAME | Flamel Technologies (FR) | 2008-06-18 | — | — | EP | claimed |
| WO-2007148341-A2 | NOVEL SEROTONIN REUPTAKE INHIBITORS AS DRUGS HAVING PERIPHERAL-SYSTEM-RESTRICTED ACTIVITY | RAMOT AT TEL AVIV UNIVERSITY LTD. (IL) | 2007-12-27 | — | — | WO | claimed |
| US-20070225379-A1 | Analgesic, Parkinson or Alzheimer drug in a solvent system containing a monoalkyl ether of diethylene glycol, a glycol, and a mixture of a C2 to C4 alcohol and water; inhibits crystallization and transfer to clothing, improves and modulates bioavailability within skin layers; nonocclusive, semi-solid | ANTARES PHARMA, INC. | 2007-09-27 | — | — | US | claimed |
| WO-2007061529-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | SCIDOSE LLC. (US) | 2007-05-31 | — | — | WO | claimed |
| US-20070116729-A1 | Lyophilization process and products obtained thereby | SCIDOSE LLC | 2007-05-24 | — | — | US | claimed |
| WO-2007036671-A2 | MICROPARTICLES WITH MODIFIED RELEASE OF AT LEAST ONE ACTIVE PRINCIPLE AND ORAL GALENIC FORM COMPRISING SAME | FLAMEL TECHNOLOGIES (FR) | 2007-04-05 | — | — | WO | claimed |
| US-6929801-B2 | Transdermal delivery of antiparkinson agents | ACRUX DDS PTY LTD (AU) | 2005-08-16 | — | — | US | claimed |
| US-20040013620-A1 | Transdermal delivery of antiparkinson agents | MONASH UNIVERSITY | 2004-01-22 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11478467-B2 | Targeted drug rescue with novel compositions, combinations, and methods thereof | HTR2A, HTR2C, CYP3A43 | SLC6A3 218/4885SLC6A4 68/4885SLC6A2 42/4885 |
| US-20230285387-A1 | COMBINATION OF MORPHINAN COMPOUNDS AND ANTIDEPRESSANT FOR THE TREATMENT OF PSEUDOBULBAR AFFECT, NEUROLOGICAL DISEASES, INTRACTABLE AND CHRONIC PAIN AND BRAIN INJURY | MAOB, DBH, OPRL1 | SLC6A3 9/4885SLC6A4 14/4885SLC6A2 4/4885 |
| US-20250032503-A1 | USE OF APREPITANT FOR TREATING ALZHEIMER'S DISEASE | TACR1, ACHE, TACR2 | SLC6A3 1329/4885SLC6A4 1763/4885SLC6A2 1338/4885 |
| US-20220296586-A1 | NOVEL COMPOSITIONS, COMBINATIONS, AND METHODS THEREOF | CYP2D6, HTR2A, CYP3A43 | SLC6A3 229/4885SLC6A4 110/4885SLC6A2 68/4885 |
| US-20040013620-A1 | Transdermal delivery of antiparkinson agents | SLC6A3, TYR, SLC18A3 | SLC6A3 1/4885SLC6A4 15/4885SLC6A2 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.